• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Juventas Therapeutics

edit

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

Recent Milestones

edit

• 
  Juventas Therapeutics received $22.2M in Series B funding. (7/16/12)
  Posted 7/16/12 at 5:18pm via finsmes.com
• 
  Juventas Therapeutics — Juventas plans $25M venture round in wake of PhI success (4/27/11)
  Posted 4/27/11 at 6:12pm via fiercebiotech.com
• 
  Juventas Therapeutics added Joseph Pastore as Director, Product Development. (10/1/07)
  Posted 4/17/13 at 4:53am
• 
  Juventas Therapeutics added Rahul Aras as President and CEO.
  Posted 4/27/11 at 6:11pm

Videos

Screenshots

edit

Sources

1. Juventas Therapeutics Closes $22.2M Series B Financing (finsmes.com) [edit]
Juventas plans $25M venture round in wake of PhI success (fiercebiotech.com) [edit]